RenovoRx Inc (NASDAQ: RNXT) is a clinical-stage medical device and drug delivery company developing localized cancer treatment technology. The company's primary asset is RenovoCath, a dual-balloon catheter delivery system designed to isolate arterial segments and deliver therapeutics directly to tumor sites, with a focus on pancreatic cancer. RenovoRx has not generated meaningful product revenue as of its FY2025 10-K filing and funds operations through equity financing. Net cash used in operating activities was $11.0 million for the year ended December 31, 2025, driven by a net loss of $11.2 million. The company is commercializing RenovoCath as a standalone device while simultaneously pursuing clinical development of combination drug-device product candidates. RenovoRx holds multiple issued and pending utility patents covering its dual-balloon catheter apparatus and Trans-Arterial Micro-Perfusion (TAMP) methods, with key U.S. patents expiring between 2030 and 2038. Headquartered in Silicon Valley, California, the company has not declared or paid any cash dividends since inception as of March 2026.

Revenue model

RenovoRx has no established commercial revenue stream as of FY2025. Operations are funded through equity financing. The company is pursuing commercialization of RenovoCath as a standalone medical device while clinical development of drug-device combination candidates continues.

Products and services

RenovoCath: a dual-balloon catheter delivery system for localized arterial drug delivery. Trans-Arterial Micro-Perfusion (TAMP): a patented method for delivering therapeutics to tumors via arterial isolation. Pipeline includes product candidates targeting pancreatic cancer and bile duct treatment.

Customers and end markets

End market is oncology, with a stated focus on pancreatic cancer treatment. Direct customers would be hospitals and interventional radiology or oncology centers, though no customer concentration data is disclosed in the filing excerpts.

Value-chain role

RenovoRx is a clinical-stage device developer. It relies on third-party manufacturers for device production and contract research organizations (CROs) for clinical trial execution. The company holds the IP and clinical development function in the value chain.

Geographic exposure

Headquartered in Silicon Valley, California. Patents filed and issued in the U.S., EU member states (BE, CH, DE, ES, FR, GB, IE, IT, NL), India, and China, indicating international IP strategy, though no commercial geographic revenue breakdown is disclosed.

Source: SEC 10-K, filed 2026-03-30

Industry: Pharmaceutical Preparations Peers: Abeona Therapeutics Inc Theriva Biologics Inc ATHERSYS, INC / NEW HUMANIGEN, INC YIELD10 BIOSCIENCE, INC. Tempest Therapeutics Inc NanoViricides, Inc VivoSim Labs Inc KINETA, INC./DE